NO980013L - Preparater og fremgangsmåter for behandling av T-cellemedierte sykdommer - Google Patents

Preparater og fremgangsmåter for behandling av T-cellemedierte sykdommer

Info

Publication number
NO980013L
NO980013L NO980013A NO980013A NO980013L NO 980013 L NO980013 L NO 980013L NO 980013 A NO980013 A NO 980013A NO 980013 A NO980013 A NO 980013A NO 980013 L NO980013 L NO 980013L
Authority
NO
Norway
Prior art keywords
cell mediated
preparations
treating
mediated diseases
methods
Prior art date
Application number
NO980013A
Other languages
English (en)
Other versions
NO320363B1 (no
NO980013D0 (no
Inventor
Irun R Cohen
Dana Elias
Meir Shinitzky
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of NO980013D0 publication Critical patent/NO980013D0/no
Publication of NO980013L publication Critical patent/NO980013L/no
Publication of NO320363B1 publication Critical patent/NO320363B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pulmonology (AREA)
  • Rehabilitation Therapy (AREA)
NO19980013A 1995-07-05 1998-01-02 Preparater for behandling av T-cellemedierte autoimmune sykdommer og anvendelse av en fettemulsjon som biologisk aktiv baerer. NO320363B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL11445895A IL114458A0 (en) 1995-07-05 1995-07-05 Therapeutic preparations for treatment of T cell mediated diseases
PCT/US1996/011373 WO1997002016A1 (en) 1995-07-05 1996-07-02 Preparations and methods for the treatment of t cell mediated diseases

Publications (3)

Publication Number Publication Date
NO980013D0 NO980013D0 (no) 1998-01-02
NO980013L true NO980013L (no) 1998-02-19
NO320363B1 NO320363B1 (no) 2005-11-28

Family

ID=11067727

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19980013A NO320363B1 (no) 1995-07-05 1998-01-02 Preparater for behandling av T-cellemedierte autoimmune sykdommer og anvendelse av en fettemulsjon som biologisk aktiv baerer.

Country Status (22)

Country Link
EP (1) EP0837672B9 (no)
JP (2) JP4357595B2 (no)
KR (1) KR100435040B1 (no)
CN (1) CN1102382C (no)
AT (1) ATE254451T1 (no)
AU (1) AU714970B2 (no)
CA (1) CA2226013C (no)
CZ (1) CZ298A3 (no)
DE (1) DE69630787T2 (no)
DK (1) DK0837672T3 (no)
ES (1) ES2211963T3 (no)
HR (1) HRP960315A2 (no)
HU (1) HU223081B1 (no)
IL (2) IL114458A0 (no)
MX (1) MX9800190A (no)
NO (1) NO320363B1 (no)
PT (1) PT837672E (no)
SI (1) SI0837672T1 (no)
UY (1) UY24275A1 (no)
WO (1) WO1997002016A1 (no)
YU (1) YU40796A (no)
ZA (1) ZA965666B (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993803A (en) * 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US6022697A (en) 1996-11-29 2000-02-08 The Regents Of The University Of California Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
ES2433915T3 (es) 2002-05-21 2013-12-13 Irun R. Cohen Vacunas de ADN que codifican proteínas de choque térmico
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004098489A2 (en) * 2003-05-12 2004-11-18 Peptor Ltd. Compositions and methods for modulation of specific epitopes of hsp60
US20090202618A1 (en) * 2003-11-24 2009-08-13 Yeda Research & Development Co. Ltd Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
EP1835933A4 (en) 2005-01-04 2015-01-07 Yeda Res & Dev HSP60, PEPTIDES HSP60 AND T-CELL VACCINES FOR IMMUNOMODULATION
AU2006293420B2 (en) 2005-09-22 2011-06-30 Irun R. Cohen Immunogenic fragments of T-cell receptor constant domains and peptides derived therefrom

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395394A (en) * 1979-10-26 1983-07-26 Pfizer Inc. Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
IL63734A (en) * 1981-09-04 1985-07-31 Yeda Res & Dev Lipid fraction,its preparation and pharmaceutical compositions containing same
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
KR19990028738A (ko) 1999-04-15
ATE254451T1 (de) 2003-12-15
HUP9802834A3 (en) 2001-08-28
AU6484496A (en) 1997-02-05
ZA965666B (en) 1997-01-27
PT837672E (pt) 2004-03-31
NO320363B1 (no) 2005-11-28
HUP9802834A2 (hu) 1999-03-29
JP2009242412A (ja) 2009-10-22
ES2211963T3 (es) 2004-07-16
HRP960315A2 (en) 1998-02-28
SI0837672T1 (en) 2004-04-30
CZ298A3 (cs) 1998-06-17
EP0837672B1 (en) 2003-11-19
CN1102382C (zh) 2003-03-05
NO980013D0 (no) 1998-01-02
EP0837672A1 (en) 1998-04-29
CA2226013A1 (en) 1997-01-23
KR100435040B1 (ko) 2004-08-18
JPH11508899A (ja) 1999-08-03
DE69630787T2 (de) 2004-10-07
DE69630787D1 (de) 2003-12-24
EP0837672B9 (en) 2005-06-15
YU40796A (sh) 1998-11-05
IL122755A (en) 2004-07-25
DK0837672T3 (da) 2004-03-22
HU223081B1 (hu) 2004-03-29
MX9800190A (es) 1998-04-30
CN1193907A (zh) 1998-09-23
IL114458A0 (en) 1995-11-27
IL122755A0 (en) 1998-08-16
WO1997002016A1 (en) 1997-01-23
UY24275A1 (es) 2000-12-29
AU714970B2 (en) 2000-01-13
JP4357595B2 (ja) 2009-11-04
EP0837672A4 (en) 1999-01-27
CA2226013C (en) 2012-09-18

Similar Documents

Publication Publication Date Title
CY1108397T1 (el) Αντι-ccr4 αντισωμα και θραυσμα αυτου
HUP0100241A2 (hu) Eljárás gyulladásos betegségek hősokk-proteinek alkalmazásával történő kezelésére
ES2153665T3 (es) Usos terapeuticos de productos proteicos bactericidas/incrementadores de la permeabilidad (bpi) para la meningococemia humana.
DK0920322T3 (da) Anvendelser af modificeret autologt blod til behandling af autoimmunitetssygdomme
ES2179077T3 (es) Acido glutamico decarboxilasa clonada.
AU1049788A (en) Methods and peptides for the treatment of non-ige-mediated diseases
DE69636514D1 (de) Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen
NO980013L (no) Preparater og fremgangsmåter for behandling av T-cellemedierte sykdommer
HUP9903378A2 (hu) Az autoimmun betegségek immunterápiájában felhasználható autoantigének és ezekkel szerkezetileg rokon fehérjék
DE69719754D1 (de) Therapeutische verwendungen von bpi-protein produkten bei menschen mit durch trauma verursachter blutung
ES2074268T3 (es) Vacunacion idiotipica contra el linfoma de celulas b.
DE69738692D1 (de) LO-CD2a ANTIKÖRPER UND DESSEN VERWENDUNGEN ZUR HEM
ES2151607T3 (es) Factor 12 de crecimiento y de diferenciacion.
DE602004023183D1 (de) Gegen antikörper gerichtete photodynamische therapie
CO4600684A1 (es) Metodo mejorado para el tratamiento y el diagnostico de en- fermedades mediadas por il-5
PT952772E (pt) Processos de utilizacao de fagocitos mononuclears para promover a regeneracao axonal
FI953093A0 (fi) Menetelmiä, joilla voidaan havaita ja hoitaa yksilöitä, joilla on epänormaaleja soluja, jotka ekspressoivat HLA-A2/tyrosinaasi-peptidiantigeenejä
FR2759701B1 (fr) Utilisation des proteines ulip dans le diagnostic et la therapie des cancers et des syndromes neurologiques paraneoplasiques
PT782630E (pt) Gene da doenca poliquistica do rim
DE60112768D1 (de) Behandlung von entzündlichen erkrankungen
FI963170A0 (fi) Menetelmä solujen poikkeavuudesta kärsivien yksilöiden tunnistamiseks i
DE69637943D1 (de) LO-CD2a Antikörper und deren Verwendung zur Hemmung der T-zellen Aktivierung und Proliferation
Wrigley et al. Normal cerebral function with bilateral carotid occlusion.
Trainin et al. Correlation between the cellular levels of cAMP, cell-mediated immunocompetence and the thymic humoral factor (THF)
DK0500921T3 (da) Na-K-ATPase-inhiberende natriuretiske substanser

Legal Events

Date Code Title Description
MK1K Patent expired